Effectively handicapping themselves in the race with Pfizer Inc. to get a kidney cancer drug to market, Onyx Pharmaceuticals Inc. and Bayer Pharmaceuticals Corp. said they plan to pursue FDA clearance of their drug based on results from an ongoing Phase III trial rather than data gleaned from the Phase II study. (BioWorld Today)